NCT00332007已完成2 期
A Single Centre, Double-blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 1
- 主要终点
- Difference in the mean number of aura attacks experienced between treatment groups
研究概览
简要总结
Overall trial objectives:
- Can treatment with tonabersat reduce the number of days with aura and/or migraine headache in patients with migraine with aura
- How well tolerated is treatment with tonabersat
The study is based on the hypothesis that the unique mechanism of action of tonabersat will inhibit some of the early events in the generation of aura and migraine headache and so be effective as prophylactic treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with an established history of migraine of at least one year meeting the diagnostic criteria of the International Classification of Headache Disorders - Edition 2 (Appendix 2) and who experience at least one aura a month.
- •Male or female patients between 18-65 years of age
- •Women of child bearing potential must be using a reliable form of contraception (defined in the protocol) for at least 3 months prior to enrolment and they must have a negative pregnancy test at screening with no intention of becoming pregnant during the study period
排除标准
- •Patients experiencing headache other than migraine or tension headache
- •Overuse of acute migraine treatments defined as more than 14 daily doses per month with analgesics or more than 9 daily doses per month of ergots or triptans within the last two months
- •Migraine prophylactic treatment within two months prior to entry to the trial
- •Patients taking any of the following medications for migraine: beta-blockers, tricyclic antidepressants (during the last 2 months), antiepileptic dugs (during the last 2 months), calcium channel blockers, monoamine oxidase inhibitors, daily NSAIDs, daily paracetamol, high dose magnesium supplements (600mg/day). Parenteral administration of botulinum toxin is also excluded. These drugs are permitted when given for diseases other than migraine provided that, in the opinion of the investigator the dose can be kept constant throughout the trial.
- •Patients who, in the opinion of the investigator, have significant cerebrovascular disease e.g. transient ischaemic attacks, stroke
- •Patients who, in the opinion of the investigator, have clinically significant cardiovascular disease
- •Patients suffering from a current clinical diagnosis of a major depressive disorder or schizophrenia
- •Patients with renal dysfunction , defined as a serum creatinine of greater than 125% of the upper limit of normal for their age group
- •Patients with hepatic dysfunction defined as a liver function test (AST, ALT, alkaline phosphatase, bilirubin) of greater than twice the upper limit of normal for their age group
- •Patients with known alcohol or other substance abuse
- •Use of an investigational drug (for any indication) within 30 days or 5 half-lives, whichever is the longer, prior to screening
- •Women who are pregnant or breast feeding
- •Women of childbearing potential not using a reliable form of contraception
- •Patients with any other clinically significant condition which, in the investigators opinion, would render them unsuitable for this study
研究组 & 干预措施
1
Experimental
Tonabersat 40 mg daily
干预措施: Tonabersat (Drug)
2
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Difference in the mean number of aura attacks experienced between treatment groups
时间窗: 12 week treatment period
Difference in the mean number of migraine headache days between treatment groups
时间窗: 12 week treatment period
Incidence of adverse events
时间窗: 12 week treatment period
次要结局
- Mean number of headache days in each treatment period.(12 week treatment period)
- Mean number of auras followed by headache in each treatment period.(12 week treatment period)
- Mean number of headache days in each month of treatment in each treatment period.(Mean monthly)
- Mean number of auras and/or migraine headache during each treatment period.(12 week treatment period)
- Mean number of migraine headache attacks in each treatment period.(12 week treatment period)
- Speed of effect of treatment.(First month for which difference between treatments identified)
- Mean monthly consumption of rescue medication.(Mean monthly)
- Mean duration of auras in each treatment period.(Mean over 12 week treatment period)
- Mean number of symptoms associated with auras in each treatment period.(12 week treatment period)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine HeadacheMigraine Without AuraMigraine With AuraNCT00311662Minster Research Ltd124
已完成
2 期
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine HeadacheMigraine Without AuraMigraine With AuraNCT00534560Minster Research Ltd542
进行中（未招募）
2 期
Evaluation of Tonabersat for DMEDiabetic Macular EdemaNCT05727891Jaeb Center for Health Research128
已完成
3 期
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt DiseaseStargardt Disease 1NCT05244304Belite Bio, Inc104
已完成
3 期
Safety and Efficacy Study of Topiramate to Aid in Smoking CessationSmoking CessationNCT00280839Lindner Center of HOPE87